Atanasio Pandiella
#165,019
Most Influential Person Now
Researcher
Atanasio Pandiella's AcademicInfluence.com Rankings
Atanasio Pandiellaphilosophy Degrees
Philosophy
#9674
World Rank
#13266
Historical Rank
Logic
#6643
World Rank
#8177
Historical Rank

Download Badge
Philosophy
Atanasio Pandiella's Degrees
- PhD Biotechnology Complutense University of Madrid
- Masters Biochemistry University of Barcelona
- Bachelors Biology University of Valencia
Similar Degrees You Can Earn
Why Is Atanasio Pandiella Influential?
(Suggest an Edit or Addition)Atanasio Pandiella's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Membrane-anchored growth factors. (1993) (703)
- Sox2 expression in breast tumours and activation in breast cancer stem cells (2012) (468)
- Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. (1993) (444)
- Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. (2002) (324)
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors (2011) (256)
- Neutrophils in cancer: prognostic role and therapeutic strategies (2017) (241)
- The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. (2006) (240)
- Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. (2006) (197)
- Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process. (1991) (191)
- Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2 (2002) (187)
- Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab (2008) (176)
- HER3 overexpression and survival in solid tumors: a meta-analysis. (2013) (170)
- Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor-α-Converting Enzyme (2000) (166)
- Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis (2014) (147)
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma (2010) (144)
- Preclinical development of molecular-targeted agents for cancer (2011) (137)
- Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors (2009) (133)
- Generation of inositol phosphates, cytosolic Ca2+, and ionic fluxes in PC12 cells treated with bradykinin. (1988) (131)
- Medicinal Plants as Sources of Active Molecules Against COVID-19 (2020) (121)
- New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. (2008) (120)
- Multiple signals activate cleavage of the membrane transforming growth factor-alpha precursor. (1991) (118)
- Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms. (1992) (116)
- The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGFα into soluble growth factor (1992) (115)
- Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target (2009) (113)
- Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma (2005) (113)
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects (2013) (109)
- TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment (1996) (107)
- Neuregulins and Cancer (2008) (107)
- Resistance to Antibody-Drug Conjugates. (2018) (106)
- P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer (2011) (96)
- Multifunctional role of Erk5 in multiple myeloma. (2005) (94)
- Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. (2008) (90)
- Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma‐Initiating Cells that Infiltrate Peritumoral Tissue (2013) (88)
- Ionic events induced by epidermal growth factor. Evidence that hyperpolarization and stimulated cation influx play a role in the stimulation of cell growth. (1991) (85)
- Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. (2017) (84)
- Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer (2014) (84)
- The effect of epidermal growth factor on membrane potential. Rapid hyperpolarization followed by persistent fluctuations. (1989) (82)
- ω‐Conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell lines (1988) (82)
- Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. (2009) (81)
- Autocrine Regulation of Membrane Transforming Growth Factor- Cleavage (*) (1996) (79)
- TGF-β1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells (2006) (76)
- ERK5 Activates NF-κB in Leukemic T Cells and Is Essential for Their Growth In Vivo1 (2006) (70)
- Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. (2005) (69)
- EGF raises cytosolic Ca2+ in A431 and Swiss 3T3 cells by a dual mechanism. Redistribution from intracellular stores and stimulated influx. (1987) (68)
- In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone (2014) (68)
- Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. (2008) (67)
- Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects (2012) (67)
- Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients (2012) (67)
- Bortezomib is an efficient agent in plasma cell leukemias (2005) (66)
- Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents (2003) (65)
- Personalized therapies in the cancer "omics" era (2010) (64)
- The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype (2008) (64)
- Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. (2002) (63)
- The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair (2009) (60)
- Endoglin Modulation of TGF-ß1-Induced Collagen Synthesis is Dependent on ERK1/2 MAPK Activation (2006) (60)
- Activated release of membrane-anchored TGF-alpha in the absence of cytosol (1993) (59)
- Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling‐competent truncated forms (1999) (58)
- Role of metalloproteinases MMP‐9 and MT1‐MMP in CXCL12‐promoted myeloma cell invasion across basement membranes (2006) (58)
- Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. (2011) (58)
- The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma (2014) (57)
- Transforming growth factor‐β1 induces collagen synthesis and accumulation via p38 mitogen‐activated protein kinase (MAPK) pathway in cultured L6E9 myoblasts (2002) (57)
- Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling (2014) (55)
- Stimulation of cleavage of membrane proteins by calmodulin inhibitors. (2000) (55)
- Endoglin Expression Regulates Basal and TGF-β1-induced Extracellular Matrix Synthesis in Cultured L6E9 Myoblasts (2004) (55)
- Voltage-operated calcium channels in small cell lung carcinoma cell lines: pharmacological, functional, and immunological properties. (1990) (54)
- Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation (2010) (53)
- Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer (2017) (52)
- Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers (2017) (52)
- Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. (2012) (51)
- Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications (2012) (51)
- ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy (2009) (50)
- Transmembrane signalling at epidermal growth factor receptors overexpressed in NIH 3T3 cells. Phosphoinositide hydrolysis, cytosolic Ca2+ increase and alkalinization correlate with epidermal-growth-factor-induced cell proliferation. (1988) (50)
- Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. (2010) (49)
- Impaired Trafficking and Activation of Tumor Necrosis Factor-α-converting Enzyme in Cell Mutants Defective in Protein Ectodomain Shedding* (2003) (48)
- Multisite phosphorylation of Erk5 in mitosis (2010) (47)
- Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor (2013) (47)
- Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. (2007) (47)
- Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer (2019) (46)
- Targeting the EGF/HER Ligand-Receptor System in Cancer. (2016) (46)
- Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications (2012) (45)
- Regulation of epidermal-growth-factor-receptor signal transduction by cis-unsaturated fatty acids. Evidence for a protein kinase C-independent mechanism. (1991) (45)
- Transmembrane signalling at the epidermal growth factor receptor. (1989) (45)
- Colorectal cancer and medicinal plants: Principle findings from recent studies. (2018) (45)
- Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. (2006) (45)
- Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. (2007) (44)
- Overexpression of HER2 signaling to WAVE2–Arp2/3 complex activates MMP-independent migration in breast cancer (2011) (44)
- A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation (2004) (44)
- Therapeutic potential of ERK5 targeting in triple negative breast cancer (2014) (44)
- ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. (2013) (43)
- Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options (2008) (43)
- Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease (2014) (43)
- Erk5 is activated and acts as a survival factor in mitosis. (2007) (42)
- Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. (2014) (42)
- TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. (2006) (41)
- Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies (2017) (41)
- NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia (2014) (40)
- HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates (2020) (39)
- Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. (2002) (38)
- The insulin‐like growth factor‐I receptor inhibitor NVP‐AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells (2008) (36)
- Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity (2008) (36)
- An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy (2020) (36)
- Deficient Spindle Assembly Checkpoint in Multiple Myeloma (2011) (36)
- A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. (2002) (35)
- Targeting HER receptors in cancer. (2012) (35)
- Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer (2017) (35)
- Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. (2020) (34)
- CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype (2012) (34)
- ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA (2017) (33)
- Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. (2014) (32)
- Second-messenger generation in PC12 cells. Interactions between cyclic AMP and Ca2+ signals. (1988) (32)
- β-Lapachone analogs with enhanced antiproliferative activity. (2012) (32)
- Trastuzumab and Antiestrogen Therapy: Focus on Mechanisms of Action and Resistance (2006) (31)
- Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis (2019) (31)
- BET inhibitors as novel therapeutic agents in breast cancer (2017) (31)
- Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis (2007) (30)
- Breast Cancer Heterogeneity and Response to Novel Therapeutics (2020) (30)
- Molecular Pathways: P-Rex in Cancer (2013) (30)
- Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. (2007) (30)
- Proteolysis targeting chimeras (PROTACs) in cancer therapy (2020) (30)
- The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. (2006) (29)
- Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study (2019) (29)
- Circulating DNA and Survival in Solid Tumors (2015) (29)
- The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. (2008) (28)
- Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? (2015) (27)
- Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression (2016) (27)
- Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment (2020) (26)
- Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. (2010) (26)
- Intracellular Calcium Homeostasis in a Human Neuroblastoma Cell Line: Modulation by Depolarization, Cholinergic Receptors, and α‐Latrotoxin (1988) (26)
- Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses (2015) (26)
- Plasma membrane hyperpolarization and [Ca2+]i increase induced by fibroblast growth factor in NIH-3T3 fibroblasts: resemblance to early signals generated by platelet-derived growth factor. (1989) (25)
- Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors (2017) (25)
- The evolving landscape of protein kinases in breast cancer: clinical implications. (2013) (25)
- Reinforcement of signal generation at B2 bradykinin receptors by insulin, epidermal growth factors, and other growth factors. (1989) (25)
- HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies (2020) (24)
- Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer (2015) (24)
- In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases (2016) (24)
- Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors (2017) (22)
- In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment (2016) (22)
- Transforming growth factor-α (1991) (21)
- Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. (1999) (21)
- Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response. (1993) (21)
- Alpha 1-adrenergic stimulation of in vitro growth hormone release and cytosolic free Ca2+ in rat somatotrophs. (1988) (20)
- Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses. (1989) (20)
- A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors (2019) (20)
- Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. (2013) (20)
- Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1 (2020) (19)
- A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. (2017) (19)
- N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity. (2005) (19)
- Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome (2019) (19)
- Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node (2016) (19)
- Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors. (2010) (19)
- Erk 5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB 2 (2001) (19)
- Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies (2016) (19)
- Antitumoral effect of Ocoxin on acute myeloid leukemia (2016) (18)
- Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer (2015) (18)
- Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine (2020) (18)
- The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential (2014) (18)
- Novel tyrosine kinase inhibitors in the treatment of cancer. (2009) (17)
- Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors (2020) (17)
- Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2 (2015) (16)
- Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling (2015) (16)
- ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor (2013) (16)
- Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response (2011) (15)
- Refining Early Antitumoral Drug Development. (2018) (14)
- Enhancement of antiproliferative activity by molecular simplification of catalpol. (2010) (14)
- Do we have to change the way targeted drugs are developed? (2010) (14)
- Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs (2021) (14)
- Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors (2017) (14)
- Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer (2018) (13)
- In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer (2021) (13)
- Transmembrane signalling at the epidermal growth factor receptor. Positive regulation by the C-terminal phosphotyrosine residues. (1991) (13)
- DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer (2016) (13)
- Transcriptome evolution from breast epithelial cells to basal-like tumors (2017) (13)
- A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers (2013) (13)
- Antiproliferative Effect of Synadenium grantii Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester (2016) (12)
- Protein kinase C-mediated feed back inhibition of the Ca2+ response at the EGF receptor. (1987) (12)
- Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. (2019) (12)
- RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications (2013) (12)
- Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results (2018) (12)
- Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer (2018) (12)
- Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors (2019) (11)
- Antitumoral effect of Ocoxin in hepatocellular carcinoma (2017) (11)
- Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors (2019) (10)
- Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy (2014) (10)
- TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. (2019) (10)
- Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer (2016) (9)
- Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. (2020) (9)
- Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer (2021) (9)
- Anticancer activity, phytochemical screening and acute toxicity evaluation of an aqueous extract of Aristolochia longa L. (2017) (9)
- CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia (2016) (9)
- Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. (2019) (9)
- Mapping Bromodomains in breast cancer and association with clinical outcome (2019) (9)
- Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer (2020) (8)
- ERK 5 / BMK 1 Is a Novel Target of the Tumor Suppressor VHL : Implication in Clear Cell Renal Carcinoma (2013) (8)
- Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells. (2002) (8)
- Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors (2015) (8)
- A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study (2017) (8)
- Modulation of cereblon levels by anti-myeloma agents (2016) (8)
- Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer (2018) (8)
- Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer (2021) (8)
- Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21 (2021) (7)
- MEK5 promotes lung adenocarcinoma (2018) (7)
- A modular approach to trim cellular targets in anticancer drug discovery. (2011) (7)
- Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin (2019) (6)
- Therapeutic potential of ERK 5 targeting in triple negative breast cancer (2014) (6)
- Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM (2011) (6)
- Multisite phosphorylation of P-Rex1 by protein kinase C (2016) (6)
- Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells. (2009) (5)
- Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications (2017) (5)
- Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene (2018) (5)
- Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells. (2005) (5)
- Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis (2020) (5)
- DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity (2008) (5)
- Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer (2021) (5)
- Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models (2019) (5)
- Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model. (2007) (5)
- PDCD4 limits prooncogenic neuregulin-ErbB signaling (2020) (5)
- MZ1 co-operates with trastuzumab in HER2 positive breast cancer (2021) (4)
- JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. (2021) (4)
- Bryonia dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA‑MB 231 breast cancer cells. (2019) (4)
- Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates (2022) (4)
- The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity. (2007) (4)
- The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation (2018) (4)
- Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors (2014) (4)
- Antimyeloma Action of the Multikinase Inhibitor TG02 (2010) (4)
- Generation of Antibody-Drug Conjugate Resistant Models (2021) (4)
- Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer. (2017) (4)
- Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs (2017) (3)
- Thyrotrophin‐Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin‐Releasing Hormone in Patients with Acromegaly or Cushing's Disease (1991) (3)
- Insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 is active in breast cancer cells and enhances growth inhibition by herceptin through an increase in cell cycle arrest (2007) (3)
- Phosphoinositide Hydrolysis and Ensuing Calcium and Potassium Fluxes: Role in the Action of EGF and Other Growth Factors (1992) (3)
- HER3 Overexpression and Survival in Solid Tumors (2012) (3)
- Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer (2020) (3)
- Expression of the beta-isoforms of Na,K-ATPase in the renal cortex of rats. (1997) (3)
- Growth Stimulation by Cell to Cell Contact and Growth Suppression: Two Aspects of the Biology of Transforming Growth Factors (1990) (3)
- Transautocrine Signaling by Membrane Neuregulins Requires Cell Surface Targeting, Which Is Controlled by Multiple Domains* (2011) (3)
- Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer (2021) (3)
- Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer (2021) (3)
- Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. (2016) (3)
- CM 363 , a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia (2017) (2)
- Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer (2022) (2)
- Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation (2021) (2)
- Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers (2022) (2)
- Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside. (2007) (2)
- β-Lapachone Analogues with Enhanced Antiproliferative Activity. (2012) (2)
- Voltage‐Operated Calcium‐Channel Subtypes in Human Neuroblastoma and Rat Pheochromocytoma Cells (1989) (2)
- Genomic Correlates of DNA Damage in Breast Cancer Subtypes (2021) (2)
- Targeting the mTOR pathway in ovarian cancer. (2010) (2)
- Achilles' heel of triple negative cancer (2014) (2)
- HER3 in cancer: from the bench to the bedside (2022) (2)
- A Small Molecule Tubulin Depolymerizing Agent Identified by a Phenotypic Drug Discovery Approach (2018) (1)
- Panobinostat (LBH589) a Promising New Partner for Combination with Doxorubicin in Acute Myeloid Leukemia. (2008) (1)
- A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumours (2019) (1)
- Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients, (2011) (1)
- Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling (2014) (1)
- Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer (2021) (1)
- Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects (2011) (1)
- Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis (2022) (1)
- Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma (2021) (1)
- Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma (2022) (1)
- An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. (2022) (1)
- Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ) (2016) (1)
- Abstract P3-14-11: Gene-expression analyses identify altered transcription factors and supports the antitumor activity of novel bromodomain inhibitors in triple negative breast cancer (2016) (1)
- 239PDA phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04 (2017) (1)
- Abstract P6-15-19: PI3K-MTOR Inhibitor BEZ235 Shows Antitumor Activity Against a Panel of Basal-Like Cells and Potentiates the Antitumor Activity of Taxanes and Vinorelbine (2010) (1)
- An update into the pathophysiological role of HER2 in cancer: therapeutic implications (2007) (1)
- Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage (2010) (1)
- Alpha-1-Adrenergic Stimulation of Cytosolic Ca2+ Concentration and Growth Hormone (GH) in Rat Somatotrophs (1989) (1)
- Antitumoral activity of EC70124, a novel multitarget kinase inhibitor, in triple-negative breast cancer. (2014) (1)
- Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer (2022) (1)
- mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. (2022) (1)
- Proteolysis targeting chimeras (PROTACs) in cancer therapy (2020) (0)
- Neuregulin (NRG) expression modulates clinical response to trastuzumab in patients with metastatic breast cancer (MBC). (2006) (0)
- Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumours with favorable outcome (2019) (0)
- Mitotic arrest induced by propargylic enol ethers derivatives (2010) (0)
- Abstract OT3-01-02: A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04 (2016) (0)
- Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells. (2006) (0)
- Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer (2022) (0)
- Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer (2021) (0)
- B195 DNA DSBs Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity (2009) (0)
- Abstract B39: Action of EC8042 in triple-negative breast cancer. (2011) (0)
- Ocoxin oral solution demonstrates antiviral properties in cellular models (2021) (0)
- Abstract 741: Targeting trastuzumab and T-DM-1 resistant breast cancer cells with EV20/MMAF, an antibody drug-conjugate against HER3 (2018) (0)
- Ionic events induced by EGF: Intracellular Ca2+ release, Ca2+ influx and membrane hyperpolarization (1990) (0)
- Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers (2017) (0)
- What about incorporating selenium in the therapeutic regimen of SARS-CoV-2? (2020) (0)
- Transforming Growth Factor (cid:2) Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab (cid:1) † (2008) (0)
- Preclinical Development Predominance of mTORC 1 over mTORC 2 in the Regulation of Proliferation of Ovarian Cancer Cells : Therapeutic Implications (2012) (0)
- 404 Multiple ErbBs Inhibition by Lapatinib Blocks Tumor Growth in Orthotopic Model of Human Testicular Germ Cell Tumour (2012) (0)
- Abstract P4-06-17: Antitumor activity of the novel mithramycin analog EC8042 in triple negative breast cancer (2012) (0)
- Role of c-Kit in Multiple Myeloma. (2006) (0)
- Abstract P6-13-18: Triple-negative kinase profile guides in the selection of the multi-kinase inhibitor EC70124 as an active antitumor agent (2016) (0)
- 1600PPHOSPHO-KINASE EXPRESSION AND ANTI-TUMORAL ACTIVITY OF THE NOVEL MULTIKINASE INHIBITOR EC-70124 IN COLON CANCER. (2014) (0)
- Lapatinib and Neratinib: Using combination drug therapy to advance the effect of the treatment of HER2 Positive Breast Cancer (2013) (0)
- Bortezomib Induces Selective Depletion of Activated T Lymphocytes and Modifies the Cytokine’s Production Pattern. (2005) (0)
- [A new antigen for the complement fixation reaction in the diagnosis of toxoplasmosis]. (1968) (0)
- Epigenetic mutational landscape in breast cancer: role of the histone methyltransferase gene KMT2D in triple negative tumors (2018) (0)
- Cancer Therapy : Preclinical NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia (2014) (0)
- Abstract A153: Effect of the multikinase inhibitor TG02 in HER2-positive breast cancer. (2011) (0)
- In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer (2019) (0)
- Neutrophils in cancer: prognostic role and therapeutic strategies (2017) (0)
- Anti-proliferative activity of bromodomain inhibitors JQ1 and OTX015 in triple negative breast cancer. (2015) (0)
- 676 HER3 Expression in Human Breast Carcinomas is Associated With Tumor Size and Estrogen Receptor Status (2012) (0)
- [Comparative study of trypanolysis and complement fixation reaction in guinea pigs infected with "Trypanosoma crusi"]. (1967) (0)
- ction of B-Chronic Lymphocytic Leukemia Cell ptosis by Arsenic Trioxide Involves Suppression of the sphoinositide 3-Kinase/Akt Survival Pathway via (2010) (0)
- Transforming growth factor-alpha. (1991) (0)
- Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease. (2009) (0)
- Ionic signals generated by growth factors: Modulation by protein kinase C (1988) (0)
- Mechanisms of Action of Growth Factors (1989) (0)
- B331 Tyrosine Kinase Inhibition in MM? Efficacy of the Combination of Dasatinib/Bortezomib/Dexamethasone (2009) (0)
- Development of 99mTcHYNIC-Tocilizumab as Imaging Agent In Multiple Myeloma (2010) (0)
- PDCD4 limits prooncogenic neuregulin-ErbB signaling (2020) (0)
- 83 Effect of TG02, a kinase inhibitor targeting Erk5, on triple negative breast cancer cells (2010) (0)
- 1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs (2015) (0)
- Mapping Bromodomains in breast cancer and association with clinical outcome (2019) (0)
- Achilles' heel of triple negative cancer (2014) (0)
- Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer (2019) (0)
- Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease (2012) (0)
- Cancer Biology and Signal Transduction Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC 1 Inhibition as an Antimyeloma Strategy (2014) (0)
- Zalypsis Possess Potent Antileukemic Effect through the Induction of a DNA Damage Response, Independently of the p53 Status. (2009) (0)
- ω-Conotoxin binding and function in human neuroblastoma and rat pheochromo- cytoma cell lines (1988) (0)
- Abstract P4-10-11: PIK3CA status as a predictor of benefit from drugs targeting the PI3K/AKT/mTOR pathway: A meta-analysis of randomized trials (2020) (0)
- Genomic mapping to identify mutations in RYR2 and AHNAK in basal-like breast tumors expressing PD-L1. (2020) (0)
- Abstract 2830: Multikinase inhibition by TG02 is therapeutically effective in two forms of breast cancer (2012) (0)
- Acadesine Inhibits Proliferation and Induces Apoptosis In Multiple Myeloma Cells, and Synergizes with Standard of Care Antimyeloma Agents (2010) (0)
- 91P Transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer (2020) (0)
- Abstract C66: Role of mTORC1 and mTORC2 in multiple myeloma and their targeting with CC214. (2011) (0)
- In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer (2021) (0)
- Pharmacological screening with Chk1 inhibitors identifies synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer (2019) (0)
- Abstract B268: Tyrosine kinase profiling in head and neck cancer tumors in combination with clinical prognosis factors guides therapeutic combination strategies (2009) (0)
- A Novel Murine Model of Human Disseminated Multiple Myeloma with A Subcutaneous Human Bone Chip from an Adult Donor Confers Proliferative Advantage and Is Suitable for the In Vivo Evaluation of Novel Drugs (2010) (0)
- 337 Differential action of ErbB kinase inhibitors on receptor oligomerization (2010) (0)
- Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors (2012) (0)
- Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors (2013) (0)
- Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma (2021) (0)
- MEMBRANE-ANCHORE D GROWTH FACTORS (1993) (0)
- A new antigen for the complement-fixation test for the diagnosis of toxoplasmosis. (1968) (0)
- Tyrosine kinase profiling guides combined therapeutic strategies in head and neck cancer. (2009) (0)
- Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer (2022) (0)
- and decreases the production of Th1 cytokines Bortezomib induces selective depletion of alloreactive T lymphocytes (2012) (0)
- Abstract 1608: Pharmacologic screening identifies synthetic lethality interactions with Chk1 inhibitors in basal-like breast and ovarian cancer (2018) (0)
- Abstract P6-05-04: Expression of the Androgen Receptor in triple negative tumors and its modulation by receptor tyrosine kinases and downstream pathways (2012) (0)
- P3-16-14: Effect of TG02, a Multikinase Inhibitor, on Triple Negative Breast Cancer Cells. (2011) (0)
- Erratum: Achilles' heel of triple negative cancer (2014) (0)
- Comparisson of Molecular Mechanisms Altered by Treatment with Different Drugs ( Doxorubicin, Melphalan, Bortezomib, Aplidin and Arsenic Trioxide ) in Multiple Myeloma Patients Using Oligonucleotide Microarrays. (2004) (0)
- Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia (2018) (0)
- 10P Genomic profiles of CD47 in breast tumours predict outcome and are associated with immune activation and enrichment of pro-tumoral macrophage markers (2020) (0)
- Abstract P6-09-49: Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer (2017) (0)
- ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology (2022) (0)
- Cancer Therapy : Preclinical Potent Antimyeloma Activity of a Novel ERK 5 / CDK Inhibitor (2013) (0)
- Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs (2017) (0)
- Traitements du myélome multiple (2009) (0)
- Genomic mapping of copy number variations influencing immune response in breast cancer (2022) (0)
- HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates (2020) (0)
- Molecular Pathways Molecular Pathways : P-Rex in Cancer (2013) (0)
- MZ1 co-operates with trastuzumab in HER2 positive breast cancer (2021) (0)
- ODZ1 supports glioblastoma progression by enhancing proliferation and migration of cancer stem-like cells (2019) (0)
- Intracellular Ca2+ homeostasis: Cell biology and activation of rapidly exchanging Ca2+ stores (1989) (0)
- What about incorporating vitamins D and C supplementation in the prevention and treatment of COVID-19? The immune response pathway (2020) (0)
- Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer (2023) (0)
- The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib (2023) (0)
- Studies on Voltage-Gated Calcium Channels by Means of Fluorescent [Ca2+]i Indicators (1988) (0)
- The IGF1-R Inhibitor AEW541 Is a Potent Anti-Myeloma Agent That Overcomes Drugs Resistance, and Has Synergistic Activity with Other New Drugs. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Atanasio Pandiella?
Atanasio Pandiella is affiliated with the following schools: